Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis

Anterior Uveitis Clinical Trial

Official title:

An Open Label Exploratory Study to Assess the Safety, Tolerability and Clinical Activity of Topically Applied ESBA105 in Patients With Acute Anterior Uveitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00823173
• Other study ID #: ESBA105CRD04
• Status: Completed
• Phase: Phase 2
• First received: January 14, 2009
• Last updated: May 25, 2011
• Start date: January 2009
• Est. completion date: December 2010

Study information

• Verified date: September 2010
• Source: ESBATech AG
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Paul-Ehrlich-InstitutGermany: Ethics Commission
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether ESBA105, a topically applied TNF-alpha inhibitor, is safe and clinically active when applied to the eye of patients suffering from acute anterior uveitis

Description:

Acute anterior uveitis (AAU) is a common, recurrent disease characterized by inflammation of the iris and ciliary body. Though usually effectively treated by topical corticosteroids, novel treatment modalities are required to overcome the limitations and adverse effect problems associated with the use of corticosteroids. TNF-alpha has been recognized as a central disease mediator in AAU, as shown by preclinical models and clinical data with systemically applied TNF-alpha inhibitors.

ESBA105 is a topically applied TNF-alpha inhibitor that is characterized by efficient penetration into the eye resulting in high intraocular drug levels. A recently completed Phase I trial confirmed that safety and tolerability of topical ESBA105 in healthy individuals is excellent and systemic exposure is low.

In this pilot trial, the safety, local tolerability and clinical activity of topical ESBA105 in the treatment of patients with acute anterior uveitis shall be explored.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: December 2010
• Est. primary completion date: December 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed and dated informed consent.

• Patients with the typical presentation of HLA-B27 positive AAU (unilateral, painful anterior uveitis of sudden onset).

• 2+ anterior chamber cells according to the SUN Working Group criteria, as assessed by slit lamp biomicroscopy.

• Start of the typical first symptoms of the current attack, defined as the point in time when the patient felt the first sensation of the attack, within the last 72 hours before initiation of treatment with the study medication.

• Negative pregnancy test for females of childbearing potential (pre menopausal, <2 years post-menopausal, not surgically sterile).

• Patients with a negative QuantiFERON TB Gold test result.

• Patients who currently have no clinically apparent symptoms of an HLA B27 associated acute extraocular disorder requiring systemic immunosuppressive therapy.

• Patients who are willing and able to cooperate with study requirements.

Exclusion Criteria:

• IOP elevation requiring therapy.

• Uncontrolled diabetes mellitus and diabetic retinopathy.

• Patients with a single eye or a pinhole Snellen visual acuity 20/200 or worse in the non study eye.

• Patients with 1+ or less anterior chamber cells.

• Patients with 3+ or 4+ anterior chamber cells or hypopyon.

• Patients in whom the time of the beginning of the current attack can not be determined.

• Patients exhibiting corneal ulceration or a history of recurrent herpetic keratitis or clinical evidence of herpetic dermatitis.

• Patients currently treated with topical corticosteroids.

• Patients treated with systemic immunosuppressive therapy within the last 2 months.

• Patients treated with a systemically administered TNF-alpha inhibitor within the last 2 months.

• Pregnant or breast-feeding women or women of childbearing potential, who with their partners refuse to use 2 reliable methods of contraception (including 1 barrier method) during the study.

• Male patients with a female partner who could become pregnant and who refuse, with their partner, to use 2 reliable methods of contraception (including 1 barrier method) during the study.

• Patients whose clinical presentation is suggestive for an active bacterial, viral or fungal infection anywhere in the body.

• Patients with history of recurrent infections, or a clinical presentation suggestive of a chronic infection requiring antimicrobial therapy (e.g. syphilis) including active episodes of serious viral infections by, e.g. herpes simplex, herpes zoster, cytomegalic or hepatitis viruses or clinical signs of fungal infections, such as histoplasmosis, aspergillosis or coccidiomycosis.

• Patients presenting with higher intraocular pressure in the uveitic eye than in the contralateral eye.

• Patients with known carrier status of human immunodeficiency virus, hepatitis B or hepatitis C.

• Patients with a history of demyelinating disease (multiple sclerosis) or optic neuritis.

• Patients with positive or unclear QuantiFERON TB Gold test result or history of high risk exposure to Mycobacterium tuberculosis.

• Patients with known coexisting malignancy.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Anterior Uveitis
• Iridocyclitis
• Iritis
• Uveitis
• Uveitis, Anterior

Intervention

Biological:
• ESBA105
ESBA105 eye drops (10mg/mL), initially applied in hourly dosing intervals, followed by later dose tapering (prolongation of dosing intervals)

Locations

Country	Name	City	State
Germany	Charité Humboldt University	Berlin
Germany	Uveitis-Zentrum Franziskus Hospital	Münster	Nordrhein-Westfalen
Germany	Universitäts-Augenklinik	Tübingen	Baden-Würtemberg

Sponsors (1)

Lead Sponsor	Collaborator
ESBATech AG

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in the level of intraocular inflammation (anterior chamber cell count according to SUN Working group criteria)		28 Days	No
Secondary	Nature and incidence of adverse events, physical and ophthalmological findings and laboratory test results		28 Days	Yes
Secondary	Systemic exposure to study drug		28 Days	Yes
Secondary	Changes in disease severity as assessed by visual analogue scale (VAS)		28 Days	No